Patients & Caregivers
Our Commitment
Innovating for You
We are working as urgently as possible to develop new therapies for patients with autoimmune diseases to help them reimagine life.
Our commitment to you is that we will:
-
Work as rapidly and efficiently as possible, because too much is at stake.
-
Honor our values in our interactions.
-
Apply our team’s deep expertise, rigor and passion to advance innovative new therapies.
-
Understand that there is not a one-size-fits-all approach to treating autoimmune diseases.
-
Stay curious and welcome opportunities to connect with you and healthcare professionals to understand your experiences and needs.
-
Stay optimistic about the possibility of delivering innovative therapies based on clinically validated science that could make a significant difference for you.
Expanded Access Policy
Expanded access, also known as “compassionate use,” refers to the use of an investigational new drug outside of a clinical trial for patients with serious or life-threatening conditions when no comparable or satisfactory alternative therapy options are available.
Zenas BioPharma is committed to studying and developing our investigational therapies as part of clinical trials designed to generate adequate safety and efficacy data to evaluate the potential benefit of the therapy versus the risk, which can then be used to support regulatory approval of the investigational therapies.
Our goal is to provide access to our investigational medicines at the appropriate time and in a safe manner. We believe enrollment in our ongoing clinical trials is the most appropriate way of achieving this goal. Therefore, we do not provide investigational medicines through expanded access programs or accept requests for access outside of our clinical trials at this time.
To learn more about Zenas’s ongoing clinical programs, please visit clinicaltrials.gov. If you have questions about participating in our clinical trials, please discuss this with your health care provider. If you have any questions regarding this policy, please contact Zenas at medinfo@zenasbio.com. Zenas plans to respond to expanded access inquiries within seven (7) business days of receipt.
If applicable, this website will be updated with hyperlinks to the relevant expanded access information on www.clinicaltrials.gov upon activation. Expanded Access Programs may vary between countries and are subject to local regulatory requirements. Zenas reserves the right to revise this expanded access policy at any time in accordance with applicable laws and regulations.
